<DOC>
	<DOCNO>NCT00779220</DOCNO>
	<brief_summary>This study evaluate efficacy , safety PK/PD ocrelizumab dose combination methotrexate（MTX）in patient active rheumatoid arthritis ( RA ) . The data study also compare clinical study ocrelizumab patient active RA conduct U.S .</brief_summary>
	<brief_title>A Study Evaluate Efficacy , Safety Pharmacokinetics/Pharmacodynamics ( PK/PD ) Ocrelizumab Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>This study evaluate efficacy , safety PK/PD ocrelizumab dose combination MTX patient active RA . The data study also compare clinical study ocrelizumab patient active RA conduct U.S .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Diagnosis RA ≧6 month accord revised 1987 ACR criterion classification RA . Adult patient , ≧20 year age . Receiving methotrexate dose 6 8mg/week（oral）for ≧12 week , stable dose last 4 week treatment . Positive serum RF . Rheumatic autoimmune disease RA , Significant systemic involvement secondary RA ( include limit vasculitis , pulmonary fibrosis , Felty 's syndrome ) .Patients secondary Sjögren 's syndrome secondary limit cutaneous vasculitis RA eligible . Functional Class Ⅳ define ACR Classification Functional Status RA . History current inflammatory joint disease RA ( e.g. , gout , reactive arthritis , psoriatic arthritis , seronegative spondyloarthropathy , Lyme disease ) systemic autoimmune disorder ( e.g. , systemic lupus erythematosus , inflammatory bowel disease , scleroderma , inflammatory myopathy , mixed connective tissue disease overlap syndrome ) . Any surgical procedure ( except minor surgery require local anaesthesia without complication sequelae ) within 12 week prior plan within 24 week baseline .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>